Bladder, Neurogenic, Spinal Cord Injuries
Conditions
Brief summary
The lower urinary tract is innervated by the autonomous (sympathetic, parasympathetic) and the somatic nervous system. Afferent information from the lower urinary tract (LUT) (e.g. filling state and volume of the urinary bladder) is conducted via the dorsal roots to the sacral spinal cord and from there to the pontine micturition center (PMC) in the brain stem. The PMC has several connections to other cortical areas. These complex interactions with the cortex enable voluntary control of the LUT and are crucial for urinary continence. The integrity of this neuronal circuit is crucial for an undisturbed function. Deterioration of the nerve fibers due to a systemic neurological disease (e.g. spinal cord injury) can affect LUT function. Neurogenic lower urinary tract dysfunction can lead to urgency, urge incontinence, reduced bladder capacity and secondary deterioration of the upper urinary tract (i.e. kidneys). First-line therapy of neurogenic detrusor overactivity contains antimuscarinic treatment. In case of side effects or remaining detrusor overactivity, nerve stimulation (e.g. sacral neuromodulation and in effect nerve tibialis stimulation) is an accepted therapy option. The precise mechanism of action of these neuro-modulatory procedures is still unknown. Utilizing state-of-the-art neuroimaging techniques, we intend to investigate the functional activation pattern after afferent tibialis nerve stimulation as well as the association with the architecture of the sacral roots. We aime to get a better insight into functional neuromodulation and central nervous processing. The study aim is to evaluate the feasibility in healthy subjects as a pilot study for the application of these method in patients with chronic, incomplete spinal cord injury.
Interventions
functional magnetic resonance imaging and diffusion tensor imaging after tibialis nerve stimulation
Sponsors
Study design
Eligibility
Inclusion criteria
* healthy volunteers * 18-50 years old * informed consent
Exclusion criteria
* history of neurological disease (eg. multiple sclerosis, epilepsy) * cardiac pacemaker, insulin or other pumps * claustrophobia * pathological findings in the uroflowmetry or post void residual assessment * medication with central nervous effects * pregnancy or lactating * unable to give informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| change in functional network connectivity | baseline; 30 minutes during nerve stimulation | change in brain network activity identified by independent component analysis |
Other
| Measure | Time frame | Description |
|---|---|---|
| gender | baseline | male or female |
| age | baseline | time since birth in years |
Countries
Switzerland